期刊文献+

甲状腺微小乳头状癌应用彩色多普勒超声联合剪切波弹性成像诊断价值探究

Diagnostic value of color Doppler ultrasonography combined with shear-wave elastography in thyroid micropapillary carcinoma
原文传递
导出
摘要 目的探讨彩色多普勒超声(CDUS)联合剪切波弹性成像(SWE)诊断甲状腺微小乳头状癌(PTMC)的价值。方法回顾性选取2020年10月至2022年12月在马鞍山十七冶医院诊治的51例PTMC患者(研究组)和同期治疗的49例甲状腺良性结节患者(对照组)为研究对象。比较两组临床资料、血清肿瘤标志物及CDUS、SWE定量参数,采用Pearson检验分析CDUS、SWE定量参数与血清肿瘤标志物的相关性,采用受试者工作特征(ROC)曲线评估CDUS、SWE定量参数诊断PTMC的价值。结果研究组血清癌胚抗原(CEA)、甲状腺球蛋白(TG)、半乳糖血凝素-3(Gal-3)水平、阻力指数(RI)、收缩期峰值流速(PSV)、弹性模量最小值(Emin)、弹性模量平均值(Emean)、弹性模量最大值(Emax)均高于对照组[(28.76±4.29)μg/L比(15.73±2.96)μg/L、(117.53±25.17)μg/L比(49.85±9.64)μg/L、(8.31±2.43)μg/L比(3.50±0.82)μg/L、0.85±0.21比0.54±0.13、(44.18±8.26)cm/s比(22.05±6.49)cm/s、(15.80±1.94)kPa比(12.97±1.58)kPa、(38.02±10.39)kPa比(23.16±7.83)kPa、(60.13±19.41)kPa比(34.65±11.87)kPa],差异有统计学意义(P<0.05)。Pearson检验结果显示,PTMC患者RI、PSV、Emin、Emean、Emax与血清CEA、TG、Gal-3水平呈正相关(P<0.05)。ROC曲线分析结果显示,RI、PSV、Emin、Emean、Emax联合诊断PTMC的曲线下面积为0.937。结论CDUS联合SWE可为临床诊断PTMC提供可靠参考依据。 Objective:To explore the value of color Doppler ultrasound(CDUS)combined with shear wave elastography(SWE)in the diagnosis of thyroid micropapillary carcinoma(PTMC).Methods:The clinical data were retrospectively collected including 51 patients with PTMC(study group)and 49 patients with benign thyroid nodules(control group)who treatment in Maanshan 17 Metallurgical Hospital from October 2020 to December 2022.The clinical data,serum tumor markers,CDUS quantitative parameters,and SWE quantitative parameters were compared between the two groups,the correlation between CDUS,SWE quantitative parameters and serum tumor markers were analyzed by Pearson test,and the diagnostic value of CDUS,SWE quantitative parameters were analyzed by receiver operating characteristic(ROC)curve.Results:The levels of serum carcinoembryonic antigen(CEA),thyroglobulin(TG),galactose hemagglutinin-3(Gal-3),resistance index(RI),peak systolic flow velocity(PSV),elasticity modulus minimum(E min),elasticity modulus mean(E mean),and elasticity modulus maximum(E max)in the study group were higher than those in the control group:(28.76±4.29)μg/L vs.(15.73±2.96)μg/L,(117.53±25.17)μg/L vs.(49.85±9.64)μg/L,(8.31±2.43)μg/L vs.(3.50±0.82)μg/L,0.85±0.21 vs.0.54±0.13,(44.18±8.26)cm/s vs.(22.05±6.49)cm/s,(15.80±1.94)kPa vs.(12.97±1.58)kPa,(38.02±10.39)kPa vs.(23.16±7.83)kPa,(60.13±19.41)kPa vs.(34.65±11.87)kPa,there were statistical differences(P<0.05).In patients with PTMC,the results of Pearson test showed that,RI,PSV,E min,E mean,and E max were positively correlated with serum CEA,TG,and Gal-3 levels(P<0.05).The results of ROC curve analysis showed that the area under the curve(AUC)of the combined diagnosis of PTMC by RI,PSV,E min,E mean,and E max was 0.937.Conclusions:CDUS combined with SWE can provide reliable reference for clinical diagnosis of PTMC.
作者 吴炎 周泉 范钰玲 盛利 张浩 陈丹 Wu Yan;Zhou Quan;Fan Yuling;Sheng Li;Zhang Hao;Chen Dan(Department of Ultrasound,Maanshan 17 Metallurgical Hospital,Maanshan 243000,China)
出处 《中国医师进修杂志》 2024年第8期705-709,共5页 Chinese Journal of Postgraduates of Medicine
关键词 乳头状甲状腺癌 甲状腺结节 超声检查 多普勒 彩色 剪切波弹性成像 诊断 Thyroid cancer,papillary Thyroid nodule Ultrasonography,Doppler,color Shear wave elastography Diagnosis
  • 相关文献

参考文献5

二级参考文献98

  • 1American Thyroid Association (ATA) Guidelines Taskforce on Thy- roid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association manage- ment guidelines for patients with thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
  • 2Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid as- sociation management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid as- sociation guidelines task force on thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
  • 3Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014[J]. J Natl Compr Canc Netw, 2014, 12(12):1671-1680.
  • 4Xing MZ. Molecular pathogenesis and mechanisms of thyroid can- cer[J]. Nat Rev Cancer, 2013, 13(3):184-199.
  • 5De Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas[J]. Thyroid, 2015, 25(9):1013- 1019.
  • 6Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34(1):28-35.
  • 7Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid [J]. Thyroid, 2003, 13(4):381-387.
  • 8Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1):42-50.
  • 9Jiang LH, Chen C, Tan Z, et al. Clinical characteristics related to central lymph node metastasis in cN0 papillary thyroid carcinoma: a retro- spective study of 916 patients[J]. Int J Endocrinol, 2014, 2014:385787.
  • 10Ito Y, Fukushima M, Higashiyama T, et al. Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of NO papillary thyroid carcinoma[J]. Endocr J, 2013, 60 (1):113-117.

共引文献421

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部